Atomoxetine for Attention-Deficit Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: a Pilot Study.

Accare, division University Center for Child and Adolescent Psychiatry, PO Box 660, 9700 AR Groningen, The Netherlands0 sites12 target enrollmentTBD

ConditionsAtomoxetine treatment.

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Atomoxetine treatment.
Sponsor: Accare, division University Center for Child and Adolescent Psychiatry, PO Box 660, 9700 AR Groningen, The Netherlands
Enrollment: 12
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Pieter W. Troost, M.D., Mark-Peter Steenhuis, M.S., Hanneke G. Tuynman-Qua, M.D., Luuk Kalverdijk, M.D., Lawrence Scahill, M.S.N., Ph.D., Jan K. Buitelaar, M.D., Ph.D., Ruud B. Minderaa, M.D. Ph. D., Pieter J. Hoekstra, M.D., Ph. D. Atomoxetine for Attention-Deficit Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: a Pilot Study. Submitted.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Accare, division University Center for Child and Adolescent Psychiatry, PO Box 660, 9700 AR Groningen, The Netherlands

Eligibility Criteria

Inclusion Criteria

•1\. Males and females between the ages of at least 6 years of age and not more than 17 years of age at visit 1;
•2\. ASD (DSM\-IV TR diagnosis of autistic disorder or Asperger’s disorder or PDD not otherwise specified, established by clinical assessment and corroborated by Autism Diagnostic Interview scores;

Exclusion Criteria

•1\. Patients who weigh less than 20 kg at study entry;
•2\. Females with a positive Beta HCG pregnancy test;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Not Applicable

Atomoxetine for Attention-deficit hyperActivity disorder Symptoms in children with pervasive developmental disorders: a pilot studyAttention Deficit Hyperactivity Disorder (ADHD), Pervasive Developmental DisordersMental and Behavioural DisordersHyperkinetic disorders

ISRCTN25479460Accare (The Netherlands)12

Terminated

Phase 4

Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALLAttention Deficit Hyperactivity Disorder

NCT00299234Monarch Medical Research1

Completed

Not Applicable

The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults ADHDAttention Deficit Hyperactivity Disorder

NCT00917371National Taiwan University Hospital60

Completed

Not Applicable

Treatment of Executive Dysfunction in Parkinson's DiseaseParkinson's Disease

NCT00286949Johns Hopkins University12

Completed

Phase 4

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional OutcomesAttention Deficit Hyperactivity Disorder

NCT00510276Eli Lilly and Company445